Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rating Increased to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Several other equities analysts also recently weighed in on BAYRY. Hsbc Global Res raised Bayer Aktiengesellschaft to a “hold” rating in a research note on Monday, April 28th. Wall Street Zen raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Friday.

Bayer Aktiengesellschaft Stock Up 0.9%

BAYRY opened at $7.59 on Thursday. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.32 and a quick ratio of 0.81. The business has a 50 day simple moving average of $6.45 and a 200-day simple moving average of $5.86. The stock has a market capitalization of $29.83 billion, a P/E ratio of -29.19 and a beta of 0.84. Bayer Aktiengesellschaft has a 12 month low of $4.79 and a 12 month high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. The firm had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. On average, equities analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Increases Dividend

The company also recently disclosed a dividend, which was paid on Monday, May 12th. Investors of record on Wednesday, April 30th were paid a $0.0224 dividend. This is an increase from Bayer Aktiengesellschaft’s previous dividend of $0.02. This represents a yield of 0.38%. The ex-dividend date of this dividend was Tuesday, April 29th. Bayer Aktiengesellschaft’s dividend payout ratio (DPR) is presently -2.17%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.